Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HDAC inhibitors modulate innate immune responses to micro-organisms relevant to chronic mucocutaneous candidiasis.

Clinical and experimental immunology - 1 Nov 2018

Rösler B, Wang X, Keating S T, Joosten L A B, Netea M G, van de Veerdonk F L

Abstract excerpt

Signal transducer and activator of transcription 1 (STAT-1) gain-of-function (GOF) mutations cause chronic mucocutaneous candidiasis (CMC), a disease associated with Candida albicans and Staphylococcus aureus infection. Patients suffer from dysegulated immune responses due to aberrant cell programming and function. We investigated the effect of inhibitory molecules targeting histone deacetylases (HDACi) on the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptive Immunity
Share to Candidiasis, Chronic Mucocutaneous

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Histone Deacetylase Inhibitors

Share to Histone Deacetylases

Share to Interleukin-22

Share to STAT1 Transcription Factor

Share to Th1 Cells

Share to Th17 Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 30069986
DOI: 10.1111/cei.13192
PMCID: PMC6194342

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDAC inhibitors modulate innate immune responses to micro-organisms relevant to chronic mucocutaneous candidiasis.PMID 30069986Read ↗

Treatment options for chronic mucocutaneous candidiasis.Semantic proximity Read ↗

Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC).Semantic proximity Read ↗

Histone Deacetylases and Their Inhibition in Candida SpeciesSemantic proximity Read ↗

Chronic mucocutaneous candidiasis disease associated with inborn errors of IL‐17 immunitySemantic proximity Read ↗

Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches.Semantic proximity Read ↗

Aberrant tolerogenic functions and proinflammatory skew of dendritic cells in STAT1 gain-of-function patients may contribute to autoimmunity and fungal susceptibility.Semantic proximity Read ↗

Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy and other primary immunodeficiency diseases help to resolve the nature of protective immunity against chronic mucocutaneous candidiasis.Semantic proximity Read ↗

A STAT1-gain-of-function mutation causing Th17 deficiency with chronic mucocutaneous candidiasis, psoriasiform hyperkeratosis and dermatophytosis.Semantic proximity Read ↗

Chronic Mucocutaneous Candidiasis in Early Life: Insights Into Immune Mechanisms and Novel Targeted Therapies.Semantic proximity Read ↗

Th2 and Th9 responses in patients with chronic mucocutaneous candidiasis and hyper-IgE syndrome.Semantic proximity Read ↗

Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.Semantic proximity Read ↗

Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.